Esperion Therapeutics (NASDAQ:ESPR) Receives “Buy” Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on ESPR. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. Finally, JMP Securities reiterated a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR traded down $0.06 during trading hours on Thursday, hitting $1.62. 1,092,766 shares of the stock were exchanged, compared to its average volume of 5,945,422. The company’s 50 day moving average is $1.86 and its 200 day moving average is $2.07. The firm has a market capitalization of $319.53 million, a P/E ratio of -2.52 and a beta of 1.04. Esperion Therapeutics has a one year low of $1.47 and a one year high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new position in shares of Esperion Therapeutics in the 3rd quarter valued at $606,000. Anson Funds Management LP acquired a new position in shares of Esperion Therapeutics in the 3rd quarter valued at $540,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Esperion Therapeutics by 71.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 295,378 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after buying an additional 241,512 shares in the last quarter. Finally, Wasatch Advisors LP raised its stake in shares of Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after buying an additional 6,483,070 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.